Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Saddi Rosa, Pedro ^a   Oliveira, Carolina Soares ^a   Crispim, Felipe ^a   Giuffrida, Fernando M A ^a,b   de Lima, Valter Correia ^a   Vieira, José Gilberto ^a   Doria, Alessandro ^c   Velho, Gilberto ^d   Reis, André Fernandes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b CEDEBA   (Brazil)

^c JOSLIN DIABETES CENTER   (United States)

^d INSERM   (France)

Author keywords

Coronary artery disease; NAMPT; rs9770242; Type 2 diabetes; Visfatin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CYTOKINE; GLUCOSE BLOOD LEVEL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENE FREQUENCY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; RISK ASSESSMENT; AGED; ANALYSIS; BLOOD; BRAZIL; CAUCASIAN; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; ODDS RATIO; PHENOTYPE; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

AGED; BIOMARKERS; BLOOD GLUCOSE; BRAZIL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYTOKINES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; UNITED STATES;

EID: 84882542091     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-119     Document Type: Article

References (41)

1. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430. 10.1126/science.1097243, 15604363.
2. De Luis DA, Sagrado MG, Aller R, Conde R, Izaola O. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle. Nutrition 2010, 26:1130-1133. 10.1016/j.nut.2008.11.019, 19211226.
3. Filippatos TD, Derdemezis CS, Gazi IF, Lagos K, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008, 38:71-72.
4. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010, 2:21. 10.1186/1758-5996-2-21, 2857825, 20346149.
5. Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Bluher S, Reinehr T, Stumvoll M, et al. Leucocytes are a major source of circulating nicotinamidephosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011, 54:1200-1211. 10.1007/s00125-010-2042-z, 3071946, 21298414.
6. Filippatos TD, Tsimihodimos V, Derdemezis CS, Gazi IF, Saougos V, Mikhailidis DP, Tselepis AD, Elisaf MS. Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile. Nutr Metab Cardiovasc Dis 2013, 23:330-336. 10.1016/j.numecd.2011.07.002, 21963513.
7. Kover K, Tong PY, Watkins D, Clements M, Stehno-Bittel L, Novikova L, Bittel D, Kibiryeva N, Stuhlsatz J, Yan Y, et al. Expression and regulation of nampt in human islets. PLoS One 2013, 8:e58767. 10.1371/journal.pone.0058767, 3594147, 23536823.
8. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, Stumvoll M, Fasshauer M. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008, 115:13-23.
9. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113:1318-1327. 398427, 15124023.
10. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008, 69:878-884.
11. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009, 71:202-207.
12. Arya R, Blangero J, Williams K, Almasy L, Dyer TD, Leach RJ, O'Connell P, Stern MP, Duggirala R. Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic mexican-americans. Diabetes 2002, 51:841-847. 10.2337/diabetes.51.3.841, 11872689.
13. Zhang YY, Gottardo L, Thompson R, Powers C, Nolan D, Duffy J, Marescotti MC, Avogaro A, Doria A. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006, 14:2119-2126.
14. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, Hudson TJ, Bouchard C, Gaudet D, Perusse L, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006, 55:2896-2902. 10.2337/db06-0189, 17003359.
15. Bottcher Y, Teupser D, Enigk B, Berndt J, Kloting N, Schon MR, Thiery J, Bluher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006, 91:2725-2731. 10.1210/jc.2006-0149, 16636125.
16. Oliveira CS, Saddi-Rosa P, Crispim F, Canani LH, Gerchman F, Giuffrida FM, Vieira JG, Velho G, Reis AF. Association of ADIPOQ variants, total and high molecular weight adiponectin levels with coronary artery disease in diabetic and non-diabetic Brazilian subjects. J Diabetes Complications 2012, 26:94-98. 10.1016/j.jdiacomp.2012.02.008, 22459242.
17. Standards of medical care in diabetes 2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
18. Pimenta JR, Zuccherato LW, Debes AA, Maselli L, Soares RP, Moura-Neto RS, Rocha J, Bydlowski SP, Pena SD. Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 2006, 62:190-195. 10.1159/000096872, 17106202.
19. Doria A, Wojcik J, Xu R, Gervino EV, Hauser TH, Johnstone MT, Nolan D, Hu FB, Warram JH. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA 2008, 300:2389-2397. 10.1001/jama.2008.649, 2762126, 19033589.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470. 10.7326/0003-4819-130-6-199903160-00002, 10075613.
21. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 2011, 412:48-52. 10.1016/j.cca.2010.09.012, 20850423.
22. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008, 158:203-207. 10.1530/EJE-07-0633, 18230827.
23. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011, 27:515-527. 10.1002/dmrr.1201, 21484978.
24. Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M, Nakagawa Y, Kihara S, Funahashi T, Komuro R, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun 2006, 349:875-882. 10.1016/j.bbrc.2006.07.083, 16970912.
25. Xiao J, Sun B, Li M, Wu Y, Sun XB. A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease. J Cell Physiol 2013, 228:495-501. 10.1002/jcp.24257, 23065734.
26. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008, 12:1395-1403. 10.1111/j.1582-4934.2008.00332.x, 2905617, 18400051.
27. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003, 35:339-341. 10.1016/S0022-2828(03)00043-9, 12689812.
28. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damas JK, Tunheim SH, Ueland T, Smith C, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980. 10.1161/CIRCULATIONAHA.106.665893, 17283255.
29. Adya R, Tan BK, Chen J, Randeva HS. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 2009, 205:113-119. 10.1016/j.atherosclerosis.2008.11.024, 19166999.
30. Cirillo P, Di Palma V, Maresca F, Pacifico F, Ziviello F, Bevilacqua M, Trimarco B, Leonardi A, Chiariello M. The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle. Thromb Res 2012, 130:403-408. 10.1016/j.thromres.2012.06.007, 22726553.
31. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Ver Nutr 2012, 32:229-243.
32. Peiro C, Romacho T, Carraro R, Sanchez-Ferrer CF. Visfatin/PBEF/Nampt: A New Cardiovascular Target?. Front Pharmacol 2010, 1:135. 3153009, 21833174.
33. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, Jang HO, Yun I, Yoon KH, Kim YJ, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007, 357:150-156. 10.1016/j.bbrc.2007.03.105, 17408594.
34. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004, 89:2563-2568. 10.1210/jc.2004-0518, 15181024.
35. Furukawa K, Hori M, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Miyazaki A, Nakayama H, Horiuchi S. Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2004, 317:831-836. 10.1016/j.bbrc.2004.03.123, 15081415.
36. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063. 10.1161/01.CIR.103.8.1057, 11222466.
37. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375. 10.1016/j.cmet.2007.09.003, 2098698, 17983582.
38. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, Hong HK, Chong JL, Buhr ED, Lee C, et al. Circadian clock feedback cycle through NAMPT-mediated NAD + biosynthesis. Science 2009, 324:651-654. 10.1126/science.1171641, 2738420, 19299583.
39. Wang LS, Yan JJ, Tang NP, Zhu J, Wang YS, Wang QM, Tang JJ, Wang MW, Jia EZ, Yang ZJ, et al. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol Biol Rep 2011, 38:819-825. 10.1007/s11033-010-0171-6, 20383745.
40. Leander K, Gigante B, Silveira A, Vikstrom M, Hamsten A, Hogberg J. NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction. Clin Chim Acta 2012, 413:727-732. 10.1016/j.cca.2012.01.002, 22251423.
41. Garcia-Bermudez M, Gonzalez-Juanatey C, Rodriguez-Rodriguez L, Miranda-Filloy JA, Perez-Esteban S, Vazquez-Rodriguez TR, Castaneda S, Balsa A, Fernandez-Gutierrez B, Llorca J, et al. Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:681-688.